1. Home
  2. HAWK vs MESO Comparison

HAWK vs MESO Comparison

Compare HAWK & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HawkEye 360 Inc. Common Stock

HAWK

HawkEye 360 Inc. Common Stock

N/A

Current Price

$14.63

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$14.29

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HAWK
MESO
Founded
2015
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2026
2005

Fundamental Metrics

Financial Performance
Metric
HAWK
MESO
Price
$14.63
$14.29
Analyst Decision
Strong Buy
Buy
Analyst Count
10
3
Target Price
$32.56
★ $37.00
AVG Volume (30 Days)
★ 1.2M
152.2K
Earning Date
11-12-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$84.87
$58.89
Revenue Next Year
$24.92
$58.93
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.21
$13.05
52 Week High
$25.71
$21.50

Technical Indicators

Market Signals
Indicator
HAWK
MESO
Relative Strength Index (RSI) 28.61 40.06
Support Level N/A $14.18
Resistance Level $17.42 $16.06
Average True Range (ATR) 0.68 0.40
MACD 0.02 -0.08
Stochastic Oscillator 2.26 9.78

Price Performance

Historical Comparison
HAWK
MESO

About HAWK HawkEye 360 Inc. Common Stock

Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: